Snapshot · Vertex Pharmaceuticals Incorporated (VRTX)

Data as of 2026-08-30T03:32:01.870Z

Fundamentals check

Market cap

$137.5B

P/E (TTM)

31.3

Gross margin

86.0%

Net margin

34.9%

ROE

23.3%

R&D / revenue

31.4%

Dividend yield

0.0%

FCF yield

2.8%

Summary

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

How it makes money

Revenue mix, latest fiscal year

• TRIKAFTA/KAFTRIO86.2%
• ALYFTREK7%
• Manufactured Product, Other6.9%

Recent Events

• 2026-08-19T00:00:00.000Zpositive

  Price move: VRTX rose 4.5%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-14T16:00:00.000Zpositive

  Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

  恰逢股价新高，市场情绪可能与对未来增长预期相关，但非直接因果。

  Source: fool.com

• 2026-08-10T00:00:00.000Zpositive

  Price move: VRTX rose 5.6%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-04T12:00:35.000Zmixed

  VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

  恰逢业绩发布，收入超预期但盈利不及预期，前景下调与上调并存。

  Source: zacks.com

• 2026-07-08T09:05:32.000Znegative

  Vertex's Crinetics Deal Balances Growth with Integration Risk

  可能与 Crinetics 收购消息相关，体现扩张计划与整合风险的潜在市场影响。

  Source: marketbeat.com

• 2026-07-02T00:00:00.000Zpositive

  Price move: VRTX rose 6.0%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-01T18:45:07.000Zpositive

  US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

  可能与 Casgevy 新适用年龄段获批相关，显示创新产品扩大市场潜力。

  Source: reuters.com

• 2026-06-22T00:00:00.000Zpositive

  Price move: VRTX rose 3.4%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-04T00:00:00.000Zpositive

  Price move: VRTX rose 3.1%

  VRTX 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $541.27 from 11 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-07-02SellMcKechnie Duncan(officer: EVP, Chief Commercial Officer)1,541 shares
• 2026-07-02SellTatsis Ourania(officer: EVP, Chief Reg. & Quality Off.)1,500 shares
• 2026-07-01SellLiu Joy(officer: EVP and Chief Legal Officer)828 shares
• 2026-06-26SellBozic Carmen(officer: EVP and CMO)596 shares
• 2026-06-18SellBozic Carmen(officer: EVP and CMO)1,020 shares

US Congress trading disclosures

• 2026-03-27Alan ArmstrongPurchase$1,001 - $15,000

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。